Imagion Biosystems Limited (IBX.AX)
AUD 0.02
(5.56%)
AUD 0.02
(5.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -3.88 Million AUD | -32.63% |
| 2022 | -3.14 Million AUD | -27.16% |
| 2021 | -2.47 Million AUD | 6.93% |
| 2020 | -2.65 Million AUD | -42.89% |
| 2019 | -1.85 Million AUD | 40.14% |
| 2018 | -3.1 Million AUD | -15542.24% |
| 2017 | 20.1 Thousand AUD | 192.94% |
| 2016 | -21.63 Thousand AUD | -493.8% |
| 2015 | 5492.60 AUD | -10.11% |
| 2014 | 6110.25 AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 651.09 Thousand AUD | 0.0% |
| 2024 Q1 | 651.09 Thousand AUD | 184.07% |
| 2023 Q2 | -414.14 Thousand AUD | 45.45% |
| 2023 Q4 | -774.47 Thousand AUD | -225.07% |
| 2023 FY | -4.16 Million AUD | -32.63% |
| 2023 Q1 | -759.15 Thousand AUD | -22.84% |
| 2023 Q3 | 619.23 Thousand AUD | 249.52% |
| 2022 Q3 | 480.37 Thousand AUD | 177.49% |
| 2022 Q2 | -619.95 Thousand AUD | 17.65% |
| 2022 FY | -3.14 Million AUD | -27.16% |
| 2022 Q1 | -752.83 Thousand AUD | -2.64% |
| 2022 Q4 | -618.01 Thousand AUD | -228.65% |
| 2021 Q2 | -375.12 Thousand AUD | -144.31% |
| 2021 FY | -2.47 Million AUD | 6.93% |
| 2021 Q4 | -733.48 Thousand AUD | 4.85% |
| 2021 Q1 | 846.62 Thousand AUD | 481.78% |
| 2021 Q3 | -770.86 Thousand AUD | -105.49% |
| 2020 Q1 | 332.01 Thousand AUD | 209.09% |
| 2020 FY | -2.65 Million AUD | -42.89% |
| 2020 Q4 | -221.76 Thousand AUD | 46.42% |
| 2020 Q3 | -413.92 Thousand AUD | 41.47% |
| 2020 Q2 | -707.21 Thousand AUD | -313.01% |
| 2019 FY | -1.85 Million AUD | 40.14% |
| 2019 Q4 | -304.35 Thousand AUD | 17.83% |
| 2019 Q3 | -370.37 Thousand AUD | 6.81% |
| 2019 Q2 | -397.43 Thousand AUD | -182.65% |
| 2019 Q1 | 480.86 Thousand AUD | 153.62% |
| 2018 Q1 | -565.32 Thousand AUD | -1252.7% |
| 2018 FY | -3.1 Million AUD | -15542.24% |
| 2018 Q4 | -896.77 Thousand AUD | 0.0% |
| 2018 Q3 | -896.77 Thousand AUD | -58.63% |
| 2018 Q2 | -565.32 Thousand AUD | -0.0% |
| 2017 Q3 | 49.04 Thousand AUD | -59.3% |
| 2017 FY | 20.1 Thousand AUD | 192.94% |
| 2017 Q2 | 120.48 Thousand AUD | 0.0% |
| 2017 Q1 | 120.48 Thousand AUD | 2297.49% |
| 2017 Q4 | 49.04 Thousand AUD | 0.0% |
| 2016 Q4 | 5025.50 AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2016 FY | -21.63 Thousand AUD | -493.8% |
| 2016 Q2 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 FY | 5492.60 AUD | -10.11% |
| 2014 FY | 6110.25 AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Australian Clinical Labs Limited | 247.36 Million AUD | 101.57% |
| BCAL Diagnostics Limited | 3.09 Million AUD | 225.339% |
| Genetic Signatures Limited | -16.2 Million AUD | 76.032% |
| Genetic Technologies Limited | 3.9 Million AUD | 199.453% |
| Healius Limited | 541.2 Million AUD | 100.718% |
| Integral Diagnostics Limited | 103.8 Million AUD | 103.741% |
| INOVIQ Ltd | -989.82 Thousand AUD | -292.304% |
| Microba Life Sciences Limited | -8.58 Million AUD | 54.754% |
| Monash IVF Group Limited | 85.5 Million AUD | 104.542% |
| Rhythm Biosciences Limited | -1.35 Million AUD | -186.076% |
| Sonic Healthcare Limited | 2.33 Billion AUD | 100.167% |